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ABSTRACT
Little information is available regarding the effect of the conditioning regimen on the outcome of bone marrow
transplantation (BMT) from an unrelated donor. Therefore, we retrospectively compared the outcome after a
cyclophosphamide/total body irradiation (Cy-TBI) regimen, an intensified Cy-TBI regimen (Cy-TBI), a
busulfan and cyclophosphamide (Bu-Cy) regimen, and a Bu-Cy regimen with total lymphoid irradiation
(Bu-Cy-TLI). Clinical data of 1875 adult patients who underwent unmanipulated unrelated BMT for leukemia
or myelodysplastic syndrome by using 1 of the 4 regimens between 1993 and 2002 were extracted from the
database of the Japan Marrow Donor Program. The effect of the conditioning regimen was adjusted for other
independent significant factors by multivariate analyses. The Cy-TBI regimen was significantly better than the
Bu-Cy regimen with regard to the incidence of engraftment failure (odds ratio, 2.49; P  .046) and overall
survival (relative risk [RR], 1.31; P  .050). The Bu-Cy-TLI regimen decreased relapse (RR, 0.13; P  .039)
but increased nonrelapse mortality (RR, 1.89; P  .0061). The Cy-TBI regimen resulted in increased
nonrelapse mortality (RR, 1.48; P  .0003) and inferior survival (RR, 1.45; P < .0001). The results of this
retrospective study suggested that the Cy-TBI regimen was superior to other regimens in unrelated BMT.
© 2005 American Society for Blood and Marrow Transplantation
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nNTRODUCTION
The conditioning regimen before allogeneic he-
atopoietic stem cell transplantation (HSCT) is in-
ended to eradicate tumor cells and to promote
mmunosuppression to prevent graft rejection. Suc-
essful bone marrow transplantation (BMT) with a
ombination of cyclophosphamide (Cy) and total body t
B&MTrradiation (TBI) was reported in the 1970s [1,2]. TBI
s effective against a variety of malignancies without
anctuary sites, such as the central nervous system and
esticles. However, there has been concern regarding
ong-term sequelae, including cataracts, second malig-
ancies, and development problems in children. Thus,
on-TBI regimens have been investigated by substi-
uting busulfan (Bu) for TBI [3,4]. Accordingly, the
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8y-TBI and Bu-Cy regimens have been regarded as
he standard conditioning regimens since the 1980s.
Four randomized controlled trials have been per-
ormed to compare the Cy-TBI and Bu-Cy regimens
n HSCT from an HLA-identical sibling donor, but
hey gave conﬂicting results with regard to both sur-
ival and toxicities [5-8]. Therefore, Hartman et al. [9]
onducted a meta-analysis of these randomized con-
rolled trials and 1 other trial that compared the eto-
oside/TBI regimen and the Bu-Cy regimen. They
howed a signiﬁcantly lower incidence of hepatic
eno-occlusive disease (VOD) after the TBI-based
egimen than the Bu-Cy regimen and a trend toward
etter survival after the TBI-based regimen (P  .09).
ecently, Socié et al. [10] updated the 4 randomized
ontrolled trials that compared the Cy-TBI and
u-Cy regimens, with a mean follow-up for surviving
atients of7 years. Although the Cy-TBI and Bu-Cy
egimens were associated with similar survival in pa-
ients with chronic myelocytic leukemia (CML), a
onsigniﬁcant (P  .068) 10% lower survival rate was
bserved after the Bu-Cy regimen in patients with
cute myeloblastic leukemia (AML).
The feasibility of the Bu-Cy regimen in unrelated
SCT has been shown in several studies, but the
ncidence of engraftment failure ranged up to 12%
11,12]. The number of patients in these studies was
mall, and there has been no randomized controlled
rial to compare conditioning regimens in unrelated
MT. Therefore, we retrospectively compared the
y-TBI and Bu-Cy regimens in a large series of pa-
ients who underwent unrelated BMT in Japan. We
lso evaluated the efﬁcacy of total lymphoid irradia-
ion (TLI), which was added to the Bu-Cy regimen to
revent engraftment failure. Another object of this
tudy was to evaluate the effect of an intensiﬁed con-
itioning regimen in which antineoplastic agents
ther than Cy, such as cytarabine, etoposide, and Bu,
ere added to the Cy-TBI regimen [13-15].
ATIENTS AND METHODS
tudy Population and Transplantation Procedure
A total of 3543 patients who underwent allogeneic
MT from an unrelated donor between 1993 and
002 for CML, AML, acute lymphoblastic leukemia
ALL), or myelodysplastic syndrome (MDS) were re-
orted to the Japan Marrow Donor Program [16-18].
hose 16 years of age, those who received a manip-
lated graft, and those who received antithymocyte
lobulin or alemtuzumab as a part of their condition-
ng regimen were excluded from the study. The con-
itioning regimens before transplantation were classi-
ed into the following groups. The Cy-TBI regimen
as deﬁned as the combination of Cy and TBI only.
he total dose of Cy was between 100 and 150 mg/kg. c
82he total dose of TBI was between 10 and 15 Gy.
y-TBI regimens were deﬁned as those that in-
luded another antineoplastic agent added to the Cy-
BI regimen. The added agent was cytarabine in
1%, etoposide in 14%, and Bu in 24% of cases. The
u-Cy regimen was deﬁned as the combination of Bu
nd Cy. The total dose of Cy was between 100 and
50 mg/kg. The total dose of Bu was 16 mg/kg in
ost patients. The Bu-Cy-TLI regimen was the com-
ination of Bu-Cy and TLI. TLI was typically per-
ormed at 5 to 8 Gy in 1 or 2 fractions. Patients who
eceived a conditioning regimen that did not belong
o these groups were excluded from the analysis. Fi-
ally, 1875 patients were included in the study.
The conditioning regimen was chosen at the dis-
retion of each center. Bone marrow was exclusively
sed as a stem cell source. Prophylaxis for graft-ver-
us-host disease (GVHD) mainly consisted of a com-
ination of cyclosporin A and methotrexate (60%) or
combination of tacrolimus and methotrexate (32%).
tatistical Considerations
Data were collected by the Japan Marrow Donor
rogram by using a standardized report form. Fol-
ow-up reports were submitted at 100 days, 1 year, and
nnually after transplantation. Data for August 2003
ere used in the following analyses. The primary end
oint was survival after transplantation. The inci-
ences of engraftment failure and grade III/IV acute
VHD, which was graded according to the published
riteria [19], were secondary end points. Engraftment
as deﬁned as a neutrophil count 500/L for 3
onsecutive days after transplantation. Engraftment
ailure was diagnosed when engraftment was not
chieved at any time after transplantation. The inci-
ences of secondary graft failure, deﬁned as persistent
eutropenia after engraftment and acute GVHD,
ere analyzed in 1744 patients who achieved initial
ngraftment.
The probability of survival and the cumulative
ncidence of acute GVHD were calculated with the
aplan-Meier method. The cumulative incidence of
elapse was calculated by Gray’s method by consider-
ng death without relapse as a competing risk [20].
nivariate comparison for dichotomous variables be-
ween groups was performed with the Fisher exact test
r the 2 test, and comparisons for time-to-event
ariables were performed with the log-rank test. Uni-
ariate analyses to compare the type of conditioning
egimen were performed to test the null hypothesis
hat the effects of each conditioning regimen were the
ame. Multivariate analyses for dichotomous and
ime-to-event variables were performed by using lo-
istic regression analysis and proportional hazards
odeling, respectively. Potential confounding factorsonsidered in the analysis included recipient age, re-
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Effect of Conditioning Regimen on Unrelated BMT
Bipient sex, donor age, donor sex, underlying disease,
isease status, serologic/genotypic HLA mismatch,
BO mismatch, cytomegalovirus serostatus, condi-
ioning regimen, cell dose in the graft, GVHD pro-
hylaxis regimen, and the use of granulocyte colony-
timulating factor (G-CSF). Acute leukemia in ﬁrst or
econd remission, CML in ﬁrst or second chronic
hase, and MDS without leukemic transformation
ere considered standard-risk diseases, whereas oth-
rs were considered high-risk diseases [21]. An HLA
ismatch in the graft-versus-host (GVH) direction
as deﬁned as when the recipient’s antigens or alleles
ere not shared by the donor, whereas mismatch in
he host-versus-graft (HVG) direction was deﬁned as
hen the donor’s antigens or alleles were not shared
y the recipient. HLA-allele mismatch included the
resence of HLA mismatch at both the antigen and
llele levels. Factors other than the type of condition-
ng regimen that showed at least borderline signiﬁ-
ance (P .10) in univariate analyses were included in
he multivariate analyses and then deleted stepwise
rom the model, except that underlying disease was
onsistently kept in the model. The type of condition-
ng regimen was added in the ﬁnal model.
ESULTS
haracteristics of the Patients
The median age of the 1875 eligible patients was
3 years (range, 16-63 years). The number of patients
ho received the Cy-TBI, Cy-TBI, Bu-Cy, and Bu-
y-TLI regimens was 714, 861, 243, and 57, respec-
ively (Table 1). A signiﬁcant difference in the pa-
ients’ background characteristics was observed with
able 1. Characteristics of the Patients (N  1875)
Variable
Cy-TBI
(n  714
ecipient sex male 63%
ecipient age >40 y 35%
onor sex male 62%
onor age >40 y 26%
LA-antigen mismatch in HVG direction 4.6%
LA-antigen mismatch in GVH direction 3.0%
LA-allele mismatch in HVG direction 35%
LA-allele mismatch in GVH direction 35%
BO major mismatch 27%
BO minor mismatch 23%
iagnosis
ALL 24%
AML 30%
CML 32%
MDS 15%
igh-risk category 17%
MV serostatus positive 80%
ell dose in the graft >3.0  108 cells/kg 46%
VHD prophylaxis: tacrolimus  methotrexate 35%
-CSF used 85%egard to recipient age, diagnosis, disease risk cate- a
B&MTory, GVHD prophylaxis regimen, and the use of
-CSF after transplantation. The Cy-TBI regimen
ended to be used in younger patients and high-risk
atients. The use of non-TBI regimens was less fre-
uent in ALL. The lower incidence of FK506-based
VHD prophylaxis and posttransplant G-CSF in pa-
ients who received the Bu-Cy-TLI regimen was
robably due to each center’s policy.
ngraftment Failure
Engraftment failure was observed in 65 patients
3.6%). Univariate analysis identiﬁed 5 risk factors
hat affected the incidence of engraftment failure with
P value of .10: higher recipient age, HLA-allele
ismatch in the HVG direction, ABO major mis-
atch, high-risk disease, and low cell dose in the graft.
y a multivariate analysis, all of these factors except
or ABO major mismatch were identiﬁed as indepen-
ent signiﬁcant risk factors for engraftment failure
Table 2). When we added the type of conditioning
egimen to this model, the use of a Bu-Cy regimen
igniﬁcantly increased the incidence of engraftment
ailure (odds ratio [OR], 2.49; 95% conﬁdence interval
CI], 1.02-6.13; P  .046). There was no signiﬁcant
ifference in the time to engraftment among the con-
itioning regimen groups (P  .26; Figure 1A).
Secondary graft failure was observed in 1.6% of
atients who achieved initial engraftment. Logistic
egression analysis revealed that only higher donor
ge was an independent signiﬁcant risk factor for sec-
ndary graft failure (OR, 2.38; 95% CI, 1.07-5.29; P
.034). The type of conditioning did not signiﬁcantly
Cy-TBI
(n  861)
Bu-Cy
(n  243)
Bu-Cy-TLI
(n  57) P Value
62% 54% 54% .069
27% 37% 44% .0005
63% 61% 56% .67
28% 30% 25% .56
4.3% 4.8% 2.0% .85
3.7% 2.7% 2.0% .82
37% 30% 24% .13
37% 31% 29% .44
28% 27% 27% .98
25% 21% 30% .41
33% 10% 0% <.0001
31% 32% 37%
26% 44% 53%
10% 14% 11%
34% 20% 16% <.0001
80% 81% 76% .81
53% 49% 46% .047
37% 32% 9% .0004
86% 86% 51% <.0001)ffect the incidence of secondary graft failure.
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8able 2. Multivariate Analyses for Engraftment Failure, Grade III/IV Acute GVHD, and Overall Survival before and after Adding the Type of
onditioning Regimen to the Model
Factor
Before After
OR (95% CI) P Value OR (95% CI) P Value
ngraftment failure
Recipient age
<40 y 1.00 1.00
>40 y 2.00 (1.05-3.80) .035 2.02 (1.06-3.88) .032
HLA-allele mismatch in HVG direction
No 1.00 1.00
Yes 3.36 (1.74-6.47) .0003 3.33 (1.72-6.45) .0003
Risk category
Standard 1.00 1.00
High 3.10 (1.50-6.41) .0023 3.40 (1.61-7.14) .0014
Cell dose
<3.0  108 cells/kg 1.00 1.00
>3.0  108 cells/kg 0.36 (0.18-0.71) .0036 0.36 (0.18-0.73) .0046
Diagnosis
ALL 1.00
AML 0.42 (0.16-1.06) .066 0.38 (0.15-0.98) .045
CML 0.58 (0.24-1.36) .21 0.50 (0.21-1.21) .12
MDS 2.51 (0.95-6.62) .063 2.33 (0.87-6.25) .094
Regimen
Cy-TBI 1.00
Cy-TBI 0.87 (0.41-1.83) .71
Bu-Cy 2.49 (1.02-6.13) .046
Bu-Cy-TLI 0.00 .98
RR (95% CI) P Value RR (95% CI) P Value
rade III/IV acute GVHD
HLA allele mismatch in GVH direction
No 1.00 1.00
Yes 1.95 (1.47-2.57) <.0001 1.96 (1.48-2.59) <.0001
ABO-minor mismatch
No 1.00 1.00
Yes 1.36 (1.01-1.82) .045 1.36 (1.01-1.83) .043
GVHD prophylaxis
Cyclosporine  methotrexate 1.00 1.00
Tacrolimus  methotrexate 0.53 (0.38-0.74) <.0002 0.53 (0.38-0.74) .0002
Diagnosis
ALL 1.00 1.00
AML 0.86 (0.55-1.32) .48 0.86 (0.55-1.33) .49
CML 1.86 (1.29-2.67) .0009 1.85 (1.27-2.68) .0014
MDS 1.41 (0.84-2.38) .19 1.44 (0.85-2.44) .17
Regimen
Cy-TBI 1.00
Cy-TBI 1.19 (0.87-1.63) .29
Bu-Cy 1.28 (0.83-1.98) .27
Bu-Cy-TLI 1.18 (0.58-2.38) .65
RR (95% CI) P Value RR (95% CI) P Value
verall survival
Recipient age
<40 y 1.00 1.00
>40 y 1.50 (1.27-1.77) <.0001 1.54 (1.31-1.83) <.0001
Donor age
<40 y 1.00 1.00
>40 y 1.20 (1.01-1.42) .036 1.17 (0.99-1.38) .074
HLA-allele mismatch in GVH direction
No 1.00 1.00
Yes 1.55 (1.32-1.82) <.0001 1.56 (1.33-1.83) <.0001
G-CSF
No 1.00
Yes 1.30 (1.04-1.64) .024 1.32 (1.05-1.67) .020
Risk category
Standard 1.00 1.00
High 2.48 (2.09-2.93) <.0001 2.31 (1.95-2.76) <.0001
GVHD prophylaxis
Cyclosporine  methotrexate 1.00 1.00
Tacrolimus  methotrexate 0.73 (0.62-0.87) .0005 0.72 (0.60-0.86) .0003
84
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Effect of Conditioning Regimen on Unrelated BMT
Bcute and Chronic GVHD
The incidence of grade II to IV and grade III/IV
cute GVHD was 43.9% and 16.7%, respectively.
ale sex, higher donor age, HLA mismatch in the
VH direction, ABO minor mismatch, underlying
isease, high-risk disease, and the GVHD prophy-
axis regimen affected the incidence of grade III/IV
cute GVHD with at least borderline signiﬁcance (P
.10). Among these, HLA-allele mismatch in the
VH direction, ABO minor mismatch, underlying
isease, and GVHD prophylaxis were identiﬁed as
able 2. (Cont’d)
Factor OR (95% C
Diagnosis
ALL 1.00
AML 0.86 (0.69-1
CML 0.82 (0.66-1
MDS 1.24 (0.93-1
Regimen
Cy-TBI
Cy-TBI
Bu-Cy
Bu-Cy-TLI
igure 1. Days to engraftment (A) and days to grade III/IV acute
tVHD (B) grouped according to the type of conditioning regimen.
B&MTndependent risk factors by a multivariate analysis
Table 2). There was no difference in the incidence
f acute GVHD among the 4 types of conditioning
egimens after adjustment for these risk factors (Ta-
le 2 and Figure 1B).
Chronic GVHD was observed in 49.7% of pa-
ients who achieved engraftment and survived dis-
ase free for at least 100 days after transplantation.
nly the presence of an HLA-allele mismatch in the
VH direction signiﬁcantly affected the incidence
f chronic GVHD by multivariate analysis. The
ype of conditioning did not signiﬁcantly affect the
ncidence of chronic GVHD.
urvival after Transplantation
Overall survival and disease-free survival at 5
ears after transplantation for all of the patients was
6.2% and 42.5%, respectively. Overall survival
tratiﬁed by disease status, grouped according to the
onditioning regimen, is shown in Figure 2. A sig-
iﬁcant difference in survival was observed in stan-
ard-risk patients. Risk factors for shorter survival
ith a P value of .10 identiﬁed by the log-rank test
ncluded male sex, higher recipient age, higher do-
or age, HLA mismatch in both the GVH and
VG directions, ABO major mismatch, high-risk
isease, cytomegalovirus seropositivity, use of G-
SF after transplantation, and GVHD prophylaxis
onsisting of cyclosporin A and methotrexate. Pro-
ortional hazard modeling identiﬁed 6 independent
igniﬁcant risk factors: higher patient age, higher
onor age, HLA-allele mismatch in the GVH di-
ection, use of G-CSF, high-risk disease, and the
se of the combination of cyclosporin A and meth-
trexate (Table 2). When we added the type of
onditioning regimen to the proportional hazard
odel, the Cy-TBI and Bu-Cy regimens were
igniﬁcantly inferior to the Cy-TBI regimen (rela-
ive risk [RR], 1.45; 95% CI, 1.20-1.74; P  .0001
nd RR, 1.31; 95% CI, 1.00-1.73; P  .050, respec-
re After
P Value OR (95% CI) P Value
1.00
.18 0.88 (0.70-1.09) .24
.063 0.84 (0.68-1.04) .11
.13 1.30 (0.98-1.74) .070
1.00
1.45 (1.20-1.74) <.0001
1.31 (1.00-1.73) .050
1.43 (0.91-2.26) .12Befo
I)
.07)
.01)
.66)ively).
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8nalyses Based on Detailed HLA Matching
We added analyses based on detailed HLA match-
ng because it has been reported that the outcome of
nrelated BMT is affected not only by the presence of
LA-allele mismatch, but also by whether the HLA-
llele mismatch belongs to class I or class II [16,18]. In
his study, none of the HLA-A/-B antigen, HLA-C
ntigen, HLA-DR antigen, HLA-A/-B allele, HLA-C
llele, or HLA-DRB1 allele mismatches in the HVG
irection signiﬁcantly affected the incidence of en-
raftment failure, probably because of the small num-
er of patients in each group. However, mismatches in
he GVH direction at the HLA-A/-B antigen, HLA-C
ntigen, HLA-A/-B allele, HLA-C allele, and HLA-
RB1 allele signiﬁcantly affected the incidence of
rade III/IV acute GVHD in univariate analyses.
hese factors were included in the multivariate anal-
sis, and HLA-A/-B allele, HLA-C allele, and HLA-
RB1 allele mismatches were shown to be indepen-
ently signiﬁcant. However, the effect of the
onditioning regimen on the incidence of grade III/IV
cute GVHD was not signiﬁcant after adjustment for
he independent signiﬁcant factors. As for survival
fter transplantation, mismatches in both the HVG
nd GVH directions at the HLA-A/-B antigen,
months
months
P
ro
ba
bi
lit
y
P
ro
ba
bi
lit
y
igure 2. Overall survival grouped according to the type of condi-
ioning regimen in standard-risk (A) and high-risk (B) patients.LA-C antigen, HLA-A/-B allele, HLA-C allele, and a
86LA-DRB1 allele signiﬁcantly affected overall sur-
ival in univariate analyses. Among these, the presence
f an HLA-A/-B antigen mismatch in the HVG di-
ection and an HLA-A/-B allele mismatch in the
VH direction were identiﬁed as independent signif-
cant risk factors for overall survival. After adjustment
or these factors, as well as other independent signif-
cant risk factors, the adverse effects of the Cy-TBI
nd Bu-Cy regimens remained signiﬁcant (RR, 1.42;
5% CI, 1.18-1.70; P  .0002 and RR, 1.31; 95% CI,
.00-1.72; P  .052, respectively).
ther Statistical Analyses to Ensure the Results
We added statistical analyses to ensure the ﬁnd-
ngs of this study. First, we repeated the analyses by
sing only patients who received the Cy-TBI or
u-Cy regimen, to conﬁrm the difference between the
regimens. The ﬁndings were almost the same, and
he use of Bu-Cy adversely affected the incidence of
ngraftment failure and overall survival (OR, 2.53;
5% CI, 1.00-6.39; P  .049 and RR, 1.32; 95% CI,
.00-1.75; P  .053, respectively).
Next, we changed the method of the multivariate
nalyses to include all factors with at least borderline
igniﬁcance (P  .10) in univariate analyses, as well as
he underlying disease and the type of conditioning
egimen, followed by a stepwise deletion of nonsignif-
cant factors. This change in the statistical method did
ot change the major ﬁndings of this study. The
u-Cy regimen was inferior to the Cy-TBI regimen in
he incidence of engraftment failure and overall sur-
ival (OR, 2.49; 95% CI, 1.02-6.12; P  .045 and RR,
.33; 95% CI, 1.02-1.75; P  .046, respectively). The
y-TBI regimen was inferior to the Cy-TBI regi-
en in overall survival (RR, 1.46; 95% CI, 1.21-1.75;
 .0001).
elapse and Nonrelapse Mortality
To evaluate the cause of the difference in survival
mong the different types of conditioning regimens,
e further analyzed the incidences of relapse and
onrelapse mortality. Multivariate analyses revealed
hat the incidence of relapse after the Bu-Cy-TLI
egimen was signiﬁcantly lower than that after the
y-TBI regimen (RR, 0.13; 95% CI, 0.02-0.90; P 
039, adjusted for ABO major mismatch, underlying
isease, disease status, and GVHD prophylaxis), al-
hough this beneﬁt was offset by a signiﬁcant increase
n the incidence of nonrelapse mortality (RR, 1.89;
5% CI, 1.20-3.00; P  .0061, adjusted for recipient
ge, donor age, underlying disease, disease status,
LA-allele mismatch in the HVG direction, G-CSF,
nd GVHD prophylaxis); this resulted in similar sur-
ival. The incidence of nonrelapse mortality after the
y-TBI regimen was signiﬁcantly higher than that
fter the Cy-TBI regimen (RR, 1.48; 95% CI, 1.20-
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Effect of Conditioning Regimen on Unrelated BMT
B.84; P  .0003, adjusted as described previously),
hereas there was no difference in the incidence of
elapse (RR, 0.84; 95% CI, 0.64-1.11; P .22). There
as no signiﬁcant difference in the incidence of re-
apse and nonrelapse mortality between the Cy-TBI
nd Bu-Cy regimens (RR, 0.89; 95% CI, 0.57-1.38; P
.59 and RR, 1.21; 95% CI, 0.89-1.65; P  .23,
espectively).
ther Complications after Transplantation
The incidence of interstitial pneumonitis was sig-
iﬁcantly different among the 4 conditioning regi-
ens (P  .019; Figure 3). The incidence of intersti-
ial pneumonitis after the Cy-TBI regimen was
igniﬁcantly higher than that after the Cy-TBI regi-
en (OR, 1.59; 95% CI, 1.13-2.23; P  .0076, ad-
usted for underlying disease, HLA-allele mismatch in
he HVG direction, and GVHD prophylaxis). A sta-
istically signiﬁcant difference was not observed be-
ween the Cy-TBI and Bu-Cy regimens (P  .66).
he incidence of VOD was also signiﬁcantly different
mong the 4 conditioning groups (P  .0049). It was
igniﬁcantly higher after the Cy-TBI, Bu-Cy, and
u-Cy-TLI regimens than after the Cy-TBI regimen
OR, 1.64; 95% CI, 1.00-2.71; P  .052; OR, 3.00;
5% CI, 1.62-5.45; P .0005; and OR, 3.20; 95% CI,
.11-8.24; P  .032, respectively, adjusted for under-
ying disease, HLA-allele mismatch in the HVG di-
igure 3. Incidence of interstitial pneumonitis, hepatic veno-occl
ymphoproliferative disorders.ection, ABO major mismatch, ABO minor mismatch, m
B&MTnd G-CSF). The incidence of hemorrhagic cystitis
as signiﬁcantly affected by the type of conditioning
egimen (P  .0003). It was also signiﬁcantly higher
fter the Cy-TBI, Bu-Cy, and Bu-Cy-TLI regimens
han after the Cy-TBI regimen (OR, 1.37; 95% CI,
.09-1.72; P  .0075; OR, 1.85; 95% CI, 1.34-2.56; P
.0002; and OR, 2.11; 95% CI, 1.16-3.85; P  .015,
espectively, adjusted for underlying disease and do-
or sex).
Secondary malignancies excluding posttransplan-
ation lymphoproliferative disorders developed in 8
atients a median of 35 months (range, 15-84 months)
fter transplantation, including MDS in 2 and AML,
hyroid cancer, uterine body cancer, esophageal can-
er, breast cancer, and squamous cell cancer in 1 each.
he incidence of secondary malignancies was not sig-
iﬁcantly different among the 4 conditioning groups.
ISCUSSION
In this study, we retrospectively evaluated the ef-
ect of the conditioning regimen on the outcome of
nrelated BMT. The Cy-TBI regimen was superior to
he Bu-Cy regimen, not only with regard to the inci-
ence of engraftment failure, but also for overall sur-
ival after transplantation. The addition of TLI to the
u-Cy regimen decreased the incidences of engraft-
ent failure and relapse but increased nonrelapse
isease, and secondary malignancies, excluding posttransplantationusive dortality. Intensiﬁed conditioning regimens in which
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8nother antineoplastic agent was added to the Cy-TBI
egimen resulted in increased nonrelapse mortality
nd inferior survival.
On the basis of the results of randomized con-
rolled trials and their meta-analysis, the Cy-TBI reg-
men is generally preferred to the Bu-Cy regimen
xcept for patients with CML in chronic phase in
SCT from an HLA-identical sibling donor [5-10].
his study showed that Cy-TBI may be the ﬁrst-
hoice regimen in most patients who undergo unre-
ated BMT unless the patient has a condition that
recludes the use of TBI, such as previous high-dose
rradiation to a major organ. The weakness of the
u-Cy regimen was apparent in the increased inci-
ences of engraftment failure and VOD. As a current
eneral practice in Japan, Bu is administered orally
ithout monitoring the plasma concentration. There-
ore, the use of intravenous Bu or oral Bu targeted to
predetermined plasma level may improve the out-
ome after the Bu-Cy regimen [22]. However, further
rials are required to evaluate the efﬁcacy of intrave-
ous Bu and targeted oral Bu.
Higher nonrelapse mortality after the intensiﬁed
y-TBI regimen might reﬂect the possibility that
he regimen was preferentially used in patients with
dvanced diseases. However, the incidence of nonre-
apse mortality was signiﬁcantly higher after adjust-
ent for disease status and also when the comparison
as limited to patients with standard-risk disease (RR,
.47; 95% CI, 1.14-1.90; P  .0031). Conversely, a
ecrease in the relapse incidence was not observed
ither in standard-risk or in high-risk patients (RR,
.81; 95% CI, 0.57-1.15; P  .24 and RR, 0.89; 95%
I, 0.57-1.39; P  .60). Therefore, these results did
ot show any beneﬁt for the intensiﬁed regimens.
This was a retrospective study, and it was impos-
ible to completely eradicate biases. First, non-TBI
egimens were preferentially used in older patients.
econd, the use of Bu-based regimens was less fre-
uent in ALL compared with myeloid malignancies.
hird, the intensiﬁed Cy-TBI regimen was most
requently used in young patients with high-risk dis-
ases. Therefore, we adjusted the effect of the condi-
ioning regimen for these variables in multivariate
nalyses. We should also consider the “center” effect
s a possible bias. However, a study from the Japan
ociety for HSCT did not show a signiﬁcant center
ffect in unrelated BMT in Japan [23]. The inclusion
f patients who underwent transplantation from 1993
nd 2002 might have resulted in the signiﬁcant vari-
tions in transplantation procedures. We could not
btain detailed information of supportive care, and
his is one of the limitations of this type of registry
ata study.
The use of G-CSF after transplantation signiﬁ-
antly adversely affected survival. A similar result was
bserved in a retrospective study by the European
88roup for Blood and Marrow Transplantation [24].
owever, such an adverse effect has not been shown
n prospective randomized controlled trials that eval-
ated the use of G-CSF after transplantation [25].
atients with preexisting infections or other comor-
idities might have tended to receive G-CSF. These
ata were not included in the analyses and thus might
ave biased the results.
Although a deﬁnite conclusion cannot be made
ithout a randomized controlled trial, 1000 patients
ill be required to detect the meaningful difference
RR, 1.31) in survival between the Cy-TBI and Bu-Cy
roups that was seen in this study at a statistically
igniﬁcant level with  and  errors of 5% and 20%,
espectively. Thus, realistically, this retrospective
tudy that considered possible biases in multivariate
nalyses may be the best evidence. More than 30 years
ave passed since the introduction of the Cy-TBI
egimen. Nevertheless, the Cy-TBI regimen still
eems to be the most suitable regimen not only in
SCT from an HLA-identical sibling donor, but also
n unrelated BMT.
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